About us
History
Leaderships
Team
EU grants
Requests for Proposal
Sustainability – ESG
Bussines strategy
Quality policy
Virtual Tour
Services
Drug Substance Manufacturing
Fill & Finish
Gene to Vial: End-to-End Development
Process Development
Analytics
Cell Line Development & Banking
Science Hub
Science News
Resources
News & Events
Press releases
Events
Content to download
Investors
Corporate documents
Shareholders and shares
Periodic reports
Current reports
Sustainability reports
Corporate governance at Mabion
Financial data
For Investors
Calendar
Contact us
Contact form
Contact for investors
Contact for media
Careers
EN
Science News
Resources
Biologics
GMP Biologics Manufacturing in End-to-End Drug Development
Biologics
,
Drug development
,
GMP
,
Manufacturing
5 Analytical Challenges in Biosimilar Characterization and Comparability
Biologics
,
Drug development
Poster
Integrated Modeling of Upstream and Downstream Bioprocessing to Improve Biologics Production Efficiency
Biologics
,
Drug development
,
Mabion
,
Manufacturing
What Can Video Games Teach Us About Contract Biopharma?
Biologics
The Role of High-Throughput Screening (HTS) in Cell Line Development and Process Optimization
Biologics
,
Drug development
Quality Control of Biologics Ensuring Safety Through Aggregation Analysis
Analytics
,
Biologics
,
GMP
,
Proteins
Co-Development Partnership Models in Biologics Programs
Biologics
,
Drug development
,
Mabion
,
Partnership
Innovative Biologics Expected Approvals in 2026
Antibody-drug conjugates
,
Biologics
,
Bispecific antibody
,
Clinical trials
,
EMA
,
FDA
,
Monoclonal antibody
,
Vaccines
EU Biotech Act Ignites a New Wave of Biologics Partnerships
Biologics
,
Clinical trials
,
EMA
,
Regulatory
1
2
3
Next